Inovio Pharmaceuticals Inc (NASDAQ:INO)’s share price hit a new 52-week high on Tuesday . The company traded as high as $34.61 and last traded at $28.05, with a volume of 1734595 shares changing hands. The stock had previously closed at $31.69.
A number of research analysts have recently weighed in on INO shares. Cantor Fitzgerald raised their price objective on Inovio Pharmaceuticals from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. ValuEngine upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Maxim Group raised their price objective on Inovio Pharmaceuticals from $18.00 to $24.00 in a research report on Tuesday, June 23rd. Piper Sandler lowered Inovio Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $8.00 price objective for the company. in a research report on Friday, March 13th. Finally, Royal Bank of Canada lowered Inovio Pharmaceuticals to a “hold” rating in a research report on Monday, April 6th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $13.56.
The company has a debt-to-equity ratio of 0.51, a quick ratio of 8.53 and a current ratio of 8.53. The firm has a market cap of $5.01 billion, a PE ratio of -24.31 and a beta of 1.39. The firm’s 50 day moving average price is $15.26 and its two-hundred day moving average price is $8.34.
Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.04). Inovio Pharmaceuticals had a negative return on equity of 166.85% and a negative net margin of 4,700.42%. The business had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.55 million. During the same quarter last year, the company earned ($0.30) earnings per share. On average, analysts forecast that Inovio Pharmaceuticals Inc will post -0.74 earnings per share for the current year.
In related news, insider Laurent Humeau sold 19,467 shares of Inovio Pharmaceuticals stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $14.70, for a total transaction of $286,164.90. Following the sale, the insider now directly owns 63,433 shares in the company, valued at approximately $932,465.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David B. Weiner sold 2,404 shares of Inovio Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of $11.84, for a total transaction of $28,463.36. Following the sale, the director now owns 827,219 shares in the company, valued at $9,794,272.96. The disclosure for this sale can be found here. 4.00% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd purchased a new stake in shares of Inovio Pharmaceuticals in the fourth quarter valued at about $37,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Inovio Pharmaceuticals in the fourth quarter valued at about $41,000. US Bancorp DE lifted its stake in shares of Inovio Pharmaceuticals by 568.3% in the first quarter. US Bancorp DE now owns 6,683 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 5,683 shares during the period. Bank of Montreal Can lifted its stake in shares of Inovio Pharmaceuticals by 29.8% in the fourth quarter. Bank of Montreal Can now owns 17,045 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 3,912 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its stake in shares of Inovio Pharmaceuticals by 19.0% in the first quarter. Ameritas Investment Partners Inc. now owns 8,259 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,318 shares during the period. Hedge funds and other institutional investors own 27.82% of the company’s stock.
Inovio Pharmaceuticals Company Profile (NASDAQ:INO)
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Article: What does an outperform rating mean?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.